ELCC 2026 Highlights Webinar-Recording

Video Transcription

Video Summary

This ISLC webinar summarized key ELCC 2026 lung cancer highlights across early-stage disease, advanced NSCLC, small cell lung cancer (SCLC), and emerging targeted strategies. Moderators Dr. Elena Linardou and Prof. Alona Zer introduced the CME-accredited session and speakers.<br /><br />Prof. Jerushka Naidoo reviewed major immunotherapy studies. Five-year updates from KEYNOTE-671 (perioperative pembrolizumab plus chemotherapy) showed excellent outcomes for patients achieving pathologic complete response (pCR), with ~81% five-year overall survival versus ~58% with placebo/chemotherapy; non-pCR patients still benefited but had lower five-year survival (~47% vs ~28%). In advanced NSCLC after chemo-immunotherapy, PRESERVE-301 suggested renewed potential for CTLA-4 inhibition: the novel agent gotistobart improved overall survival versus docetaxel in a small squamous subgroup, with expected immune toxicities. By contrast, the phase III LATIFY trial (ATR inhibitor serralacertib + durvalumab) did not improve PFS or OS versus docetaxel, though a small subset had durable responses, underscoring the need for biomarkers. ETOP’s I-TIMES pooled analysis found no survival difference between morning vs afternoon immunotherapy administration.<br /><br />Dr. Yannis Moutzios highlighted ADCs and SCLC innovation: biomarker-selected TROP2 ADC trials (e.g., Tropion Lung 17), DLL3-targeted T-cell engager combinations (including first-line phase III plans with tarlatamab), and striking early chemo-free first-line SCLC activity with an EGFR/HER3 bispecific ADC plus PD-1 therapy.<br /><br />Dr. Adrian Sacher presented KRAS G12C, EGFR exon 20, and HER2 updates, including promising early data for caldorasib combinations with pembrolizumab and emerging efficacy/CNS activity of newer exon 20 agents.<br /><br />Finally, Dr. Antonio Passaro framed ELCC’s broader shift toward biology-driven “precision strategy,” treatment trajectories, and learning from both positive and negative trials.

Keywords

ELCC 2026

lung cancer webinar

perioperative pembrolizumab

KEYNOTE-671

pathologic complete response (pCR)

advanced NSCLC

CTLA-4 inhibition

gotistobart

small cell lung cancer (SCLC)

antibody-drug conjugates (ADCs)

KRAS G12C